FindTrial
Sign In

Prevalence of adrenal insufficiency and thyroid dysfunction in post COVID-19 infection

Prevalence of adrenal insufficiency and thyroid dysfunction in post COVID-19 infection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20220606002
Enrollment
92
Registered
2022-06-06
Start date
2022-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adrenal insufficiency thyroid dysfunction post-covid-19 patients adrenal insufficiency thyroid dysfunction post-covid-19 patients

Interventions

Participants who have been infected with covid-19 for 3 months
Diagnostic
post covid-19 patients

Sponsors

Chulabhorn Royal Academy
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Post covid-19 patients, 3 months apart

Exclusion criteria

Exclusion criteria: on glucocorticoid therapy History of adrenal disease or pituitary disease chronic kidney disease (Creatinine > 1.5 mg/dl) chronic liver disease on medication such as anti epileptic drugs or oral contraceptive drug pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
prevalence of adrenal insufficiency 3 months low dose ACTH stimulation test—

Secondary

MeasureTime frame
thyroid dysfunction 3 months thyroid stimulating hormone—

Countries

Thailand

Contacts

Public ContactThachanun Porntharukchareon

Chulabhorn Royal Academy

thachanun.por@cra.ac.th025766000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026